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Summary
Increasing evidence implicates chronic energetic dysfunction in human cardiac ar-
rhythmias. Mitochondrial impairment through Pgc-1β knockout is known to produce a 
murine arrhythmic phenotype. However, the cumulative effect of this with advancing 
age and its electrocardiographic basis have not been previously studied. Young (12- 
16 weeks) and aged (>52 weeks), wild type (WT) (n = 5 and 8) and Pgc-1β−/− (n = 9 and 
6), mice were anaesthetised and used for electrocardiographic (ECG) recordings. Time 
intervals separating successive ECG deflections were analysed for differences be-
tween groups before and after β1- adrenergic (intraperitoneal dobutamine 3 mg/kg) 
challenge. Heart rates before dobutamine challenge were indistinguishable between 
groups. The Pgc-1β−/− genotype however displayed compromised nodal function in 
response to adrenergic challenge. This manifested as an impaired heart rate response 
suggesting a functional defect at the level of the sino- atrial node, and a negative 
dromotropic response suggesting an atrioventricular conduction defect. Incidences of 
the latter were most pronounced in the aged Pgc-1β−/− mice. Moreover, Pgc-1β−/− mice 
displayed electrocardiographic features consistent with the existence of a pro- 
arrhythmic substrate. Firstly, ventricular activation was prolonged in these mice con-
sistent with slowed action potential conduction and is reported here for the first time. 
Additionally, Pgc-1β−/− mice had shorter repolarisation intervals. These were likely at-
tributable to altered K+ conductance properties, ultimately resulting in a shortened 
QTc interval, which is also known to be associated with increased arrhythmic risk. ECG 
analysis thus yielded electrophysiological findings bearing on potential arrhythmo-
genicity in intact Pgc-1β−/− systems in widespread cardiac regions.
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1  | INTRODUCTION
Cardiac arrhythmias result from disruption of the normally coordinated 
sequence of atrial and ventricular excitation, often following altered 
ion channel function. The most common of these, atrial fibrillation 
(AF), affects in excess of 8 million individuals in Europe, and accounts 
for one in three arrhythmia- related hospital attendances. Similarly, 
ventricular arrhythmias are the commonest cause of sudden cardiac 
death (SCD), with a worldwide incidence of >300 000 deaths/year.1,2
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Previous physiological analyses of arrhythmic tendency had stud-
ied murine hearts with varying monogenic ion channel disorders mod-
elling arrhythmic mechanisms associated with a number of inherited 
channelopathies. However growing evidence implicates the energetic 
dysfunction known to occur with both ageing and some common age- 
related chronic conditions in the increased incidences of both atrial and 
ventricular arrhythmias with age. Chronic conditions including obesity, 
diabetes mellitus and heart failure themselves constitute independent 
pro- arrhythmic risk factors.3 All these conditions are associated with de-
teriorating metabolic, particularly mitochondrial function. Mitochondria 
from cardiomyocytes of AF patients showed increased DNA damage,4 
structural abnormalities5 and impaired function.4 Similarly, patients 
with inherited mitochondrial disorders such as Kearns- Sayre Syndrome 
show increased risks of fatal ventricular arrhythmia.6
Peroxisome proliferator activated receptor- γ coactivator- 1 
(PGC- 1) transcriptional coactivators offer strategic targets for 
electrophysiological studies in such energetically deficient hearts. 
The PGC- 1 family includes PGC- 1α and PGC- 1β; these are highly 
expressed in oxidative tissues such as the heart, brain and skele-
tal muscle. They are key regulators of mitochondrial mass, func-
tion, and cellular metabolism.7 They interact with cardiomyocyte 
nuclear receptor factor- 1, estrogen related receptor- α and per-
oxisome proliferator- activated receptor- α in increasing mitochon-
drial biogenesis.8 They also upregulate expression of nuclear and/
or mitochondrial- encoded mitochondrial proteins involved in fatty 
acid β- oxidation, the tricarboxylic acid cycle and electron transport.9 
PGC- 1 protein expression and the corresponding mitochondrial ac-
tivity, is coordinated with several upstream stimuli reflecting the 
heart’s energetic demand.10 Conversely, obesity, insulin resistance, 
type II diabetes mellitus, and ageing are associated with reduced 
PGC- 1 protein expression and mitochondrial dysfunction.11
Overexpression of some PGC- 1 family members results in in-
creased mitochondrial density and oxidative capacity.12 Conversely, 
mice deficient in both Pgc-1α and Pgc-1β develop a perinatally lethal 
low cardiac output state and conduction disease.13 Cardiac pheno-
types of mice lacking individual members of the PGC- 1 family are 
less severe. Pgc-1α deficient murine hearts show normal baseline 
contractile function but develop cardiac failure following increased 
afterload.9 Studies on Pgc- 1β deficient hearts are more limited, but 
nevertheless report normal baseline cardiac function despite their 
reduced mitochondrial content, but blunted heart rate responses 
following adrenergic stimulation.14 Furthermore, Langendorff- 
perfused Pgc-1β−/− hearts demonstrated increased arrhythmic pro-
pensity reflected in action potential (AP) duration alternans and 
increased frequencies of ventricular tachycardia (VT) following pro-
grammed electrical stimulation.14 Isolated Pgc-1β−/− cardiomyocytes 
also showed altered ion channel expression patterns, spontaneous 
diastolic Ca2+ transients, and pro- arrhythmic after- depolarisation 
events.15 The combination of apparently normal baseline contractile 
function but potentially pro- arrhythmic electrophysiological abnor-
malities make Pgc- 1β deficient hearts attractive models to investi-
gate roles of mitochondrial impairment in arrhythmia in an absence 
of a confounding cardiac failure.
Murine electrocardiography (ECG) and analysis of ECG waveforms 
have proven useful in investigating electrophysiological changes as-
sociated with experimental cardiac disease.16 Murine ECGs differ in 
their sinus rates and action potential waveforms17,18 but neverthe-
less can be used to clarify alterations in heart rate, its variability, and 
timings in the cardiac excitation sequence. Thus, their P- waves, and 
PR, QRS and QT intervals, continue to reflect atrial and ventricular, 
depolarisation and repolarisation whose alterations could reflect po-
tentially pro- arrhythmic electrophysiological changes. Alterations in 
murine ECG waveforms have thus proven useful in studying murine 
models for the Brugada syndrome,19,20 long QT syndrome type 321 
and catecholaminergic polymorphic ventricular tachycardia.22
The present study investigates ECG changes associated with the 
energetic dysfunction occurring with Pgc-1β ablation. As the under-
lying chronic mitochondrial lesions likely exert cumulative phenotypic 
effects with advancing age, we studied both young and aged, WT and 
genetically modified animals both at baseline and following adrenergic 
stress. This provided additional insights into possible interactions be-
tween genotype and ageing.
2  | RESULTS
There were no significant differences in weights between different 
experimental groups, whether stratified by age or genotype. Aged 
Pgc-1β−/− mice had a mean weight of 35.49 ± 1.44 g compared to 
35.57 ± 1.13 g for aged WT mice. Young Pgc-1β−/− and WT mice 
had mean weights of 31.30 ± 1.56 g and 35.31 ± 2.26 g respec-
tively. The complete ECG records confirmed sinus rhythm as the 
predominant rhythm (Figure 2A) with ECG complexes including 
clearly identifiable deflections as reported on earlier occasions52 
(Figure 1). Two mice, both aged Pgc-1β−/−, showed multiple ectopic 
beats (Figure 2B) (Table 1). This initial analysis also confirmed that 
ST segment changes that might signal acute ischaemic change never 
occurred prior to dobutamine challenge. ST segment depression oc-
curred in a small number of both WT and Pgc-1β−/− aged mice fol-
lowing such challenge (Figure 2D, E).
2.1 | Pgc-1β−/− hearts display impaired heart 
rate responses
Chronotropic incompetence is an established clinical feature of car-
diac failure, although it can also occur in association with other cardiac 
pathology. It has been variably defined, but is commonly identified 
as a failure to reach an arbitrary percentage of the predicted maxi-
mum heart rate following sympathetic challenge, ranging from 70% 
to 85%.23 A previous study had reported an impaired chronotropic 
response in isolated ex vivo Pgc-1β−/− hearts challenged with dobu-
tamine. These findings had not been statistically significant at a 10 ng/
kg per minute infusion rate and depended on single heart rate record-
ings at each predefined, time point.14 The present experiments sys-
tematically analysed steady state parameters over 5- minute recording 
periods before and following dobutamine challenge in intact animals.
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Figure 3 shows typical heart rate profiles at baseline and in re-
sponse to dobutamine for each experimental group. As there is no 
algorithm predicting normal murine heart rates at different ages as 
there is with humans, we assessed the chronotropic responses to 
dobutamine challenge using two different parameters: (i) peak heart 
rate attained after dobutamine administration; and (ii) mean heart rate 
observed post- dobutamine administration. Figure 4 plots mean heart 
rates observed before dobutamine challenge against results obtained 
following dobutamine challenge for each individual animal. Pgc-1β−/− 
animals displayed a tendency to slower basal heart rates under both 
conditions. A Pearson product- moment correlation coefficient assess-
ing the co- variance between mean heart rates before and following 
dobutamine challenge demonstrated a positive association between 
variables, (r = .692, P < .0001). Lower resting heart rates thus cor-
related with lower heart rates after dobutamine challenge.
MANOVA demonstrated significant effects of genotype (P = .022) 
and age (P = .048) on steady state heart rates (Table 2A). Post hoc 
Tukey tests demonstrated that genotype and age neither exerted inde-
pendent nor interacting effects upon baseline steady state heart rates. 
In contrast, genotype exerted independent effects, with the Pgc-1β−/− 
mutation reducing heart rates observed following dobutamine chal-
lenge (Pgc-1β−/− 8.30 ± 0.28 Hz, n = 15; WT, 9.11 ± 0.11 Hz, n = 13; 
P = .021; Figure 5). In contrast, there were no significant effects of ei-
ther age or interactions between age and genotype. Similarly, ANOVA 
demonstrated independent significant effects of genotype (P = .011) 
but not either age or interactive effects between genotype and age 
on maximum heart rates attained after dobutamine challenge. Thus, 
post hoc tests demonstrated lower peak heart rates in Pgc-1β−/− than 
WT mice (mean peak heart rate 8.47 ± 0.28 Hz vs 9.53 ± 0.21 Hz, 
P = .0084, n = 13 vs 15 respectively).
Heart rate variabilities, reflecting autonomic influences on the 
heart, and known to be related to adverse mortality risk, expectedly 
altered within each experimental group following dobutamine chal-
lenge. However, the respective findings obtained before or follow-
ing dobutamine did not vary between experimental groups. This was 
reflected in Poincare plots constructed for each mouse (Figure 6A, 
B), exemplified in pre- (A) and post- dobutamine (B), young (a,b) and 
aged (c,d), WT (a,c) and Pgc-1β−/− mice (b,d). The dispersion of these 
points was quantified by the standard deviation of the ΔRR interval 
before (Figure 6C) and following dobutamine challenge (Figure 6D). 
ANOVA demonstrated no significant differences in such dispersions 
before or after dobutamine addition between different experimental 
groups. These results attribute the present findings to an existence of 
sino- atrial node (SAN) as opposed to autonomic dysfunction in the 
Pgc-1β−/− mice.
2.2 | Age- related SA node disease in WT and Pgc-
1β−/− murine hearts
Although sinus rhythm was the prevailing rhythm in all groups, both 
WT and Pgc-1β−/− mice demonstrated intermittent episodes of iso-
rhythmic AV dissociation24 during the recording period. These epi-
sodes predominantly occurred in aged animals, affecting 3/6 aged WT 
mice and 4/8 aged Pgc-1β−/− mice, but in only one young Pgc-1β−/− and 
none of the young WT mice (Table 1). They most frequently occurred 
immediately following dobutamine challenge, whilst RR intervals were 
decreasing from their baseline, pre- treatment values. During these 
episodes, RR intervals were shorter than their corresponding PP in-
tervals, but the ventricular complexes remained identical to those 
observed during sinus rhythm. The latter suggests a supraventricular 
(likely junctional) pacemaker focus driving such activity (Figure 2C).
2.3 | Pgc-1β−/− hearts display paradoxical 
atrioventricular node function
MANOVA analysis indicated that P- wave durations were not af-
fected by either independent or interacting effects of age or geno-
type, whether before or following dobutamine challenge (Table 2B). 
In contrast, two alteration patterns of altered PR interval reflecting 
atrioventricular node (AVN) function were observed with dobu-
tamine administration. These took the form of either positive or 
negative dromotropic effects of dobutamine appearing as increases 
F IGURE  1 Typical ECG and definition of deflections used in 
quantitative analysis (A) start of P- wave; (B) P- wave trough/end of 
P- wave; (C) start of QRS complex; (D) R wave peak; (E) trough of S 
wave; (F) peak of R’ deflection; (G) C wave peak; (H) trough or end of 
C wave. The corrected QT interval, QTc is taken as the interval from C 
to H and corrected for RR intervals52
B C
D
E
G HA
F
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or decreases in PR interval (Figure 7), taking place despite unchanged 
P- wave durations that were similar between experimental groups sug-
gesting a continued normal atrial conduction (Table 2B).
MANOVA indicated that neither age nor genotype affected PR in-
terval whether before or following dobutamine challenge (Table 2C). 
Nevertheless, the alteration in PR interval following dobutamine chal-
lenge demonstrated differing responses from WT and Pgc-1β−/− mice. 
All young (5 of 5) and aged (6 of 6) WT mice showed decreased PR 
intervals following dobutamine challenge. In contrast, the PR interval 
decreased in 5 of 9 and increased in the remaining four young Pgc-
1β−/− mice. In aged Pgc-1β−/− mice the result was even more marked 
with only one mouse showing the expected positive dromotropic ef-
fect with dobutamine administration and 5 of 6 mice showing a par-
adoxical negative dromotropic effect in response to dobutamine. In 
addition to the SAN dysfunction seen with the Pgc-1β knockout there 
was compromised AVN conduction in a subset of mutant hearts, an 
effect exacerbated by increasing age.
The presence of AVN dysfunction in mutant mice which also 
demonstrated impaired heart rate responses led us to examine 
whether paradoxical AV node dysfunction underlies or is associated 
with the blunted chronotropic responses. Such a comparison demon-
strated that Pgc-1β−/− animals with a normal AVN response showed 
a mean heart rate of 9.10 ± 0.22 Hz (n = 6) following dobutamine 
challenge. In contrast, Pgc-1β−/− animals with a paradoxical AVN re-
sponse to dobutamine showed a heart rate of 7.77 ± 0.34 Hz (n = 9). A 
two- tailed student t test confirmed that the difference was significant 
(P = .0061). Thus these findings suggest that the Pgc-1β−/− mutation is 
associated only with significantly altered AV nodal function in a subset 
of mutant mice, and that the presence of AV nodal dysfunction itself 
may be a marker for impaired heart rate responses.
2.4 | Aged Pgc-1β−/− hearts display slowed 
ventricular activation
Ventricular activation is a synchronised, sequential process, whose 
onset is easily detected as the beginning of the Q wave deflection 
(Figure 1). Ventricular recovery is considered to begin at a time-
point between the S wave trough, and the beginning of the R’ peak. 
F IGURE  2 Typical ECG records from Pgc-1β−/− heart illustrating (A) normal sinus rhythm; (B) ectopic beat; (C) atrioventricular (AV) 
dissociation; records obtained from the same mouse. Arrows indicate timings of P- waves (D) pre- dobutamine and (E) following dobutamine 
challenge with ECG showing ST depression
(A)
(C)
(D)
(E)
0.1s
(B)
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Examination of three independent ECG indicators, of QR, QS and 
QR’ durations, of ventricular activation, suggested interacting effects 
of age and genotype upon its duration (Table 3). MANOVA demon-
strated that genotype and age, whilst not exerting independent ef-
fects, showed interacting effects upon all the three parameters of 
TABLE  1  Incidence of particular electrocardiographic features in 
the experimental groups
WT Pgc-1β−/−
Young Aged Young Aged
(A) Ischaemic change
Ischaemic changes 
present
0 2 0 2
Ischaemic changes 
absent
5 6 9 4
(B) Arrhythmic ECG patterns
Sinus rhythm only 5 4 8 3
Isorhythmic AV 
dissociation
0 4 1 3
Ectopic beats 0 0 0 1
Electrocardiographic records obtained at baseline prior to pharmacological 
intervention in young WT (n = 5), aged WT (n = 8), young Pgc-1β−/− (n = 9) 
and aged Pgc-1β−/− (n = 6).
F IGURE  3 Traces plotting heart rate response curves before and following dobutamine challenge in (A) young WT, (B) aged WT; (C) young 
Pgc-1β−/− and (D) aged Pgc-1β−/− mouse
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F IGURE  4 Correlations between heart rates observed pre- vs 
post- dobutamine challenge in Pgc-1β−/− and WT
6
7
8
9
10
4 5 6 7 8 9
Mean Heart Rate − Pre Dobutamine (Hz)
M
ea
n 
H
ea
rt 
R
at
e 
− 
Po
st
 D
ob
ut
am
in
e 
(H
z)
Aged Mutant
Aged Wild Type
Young Mutant
Young Wild Type
     |  179AHMAD et Al.
QR (P = .032), QS (P = .040) and QR’ duration (P = .039). This was 
also the case with QR, QS, but not QR’ (QR: P = .029; QS: P = .029; 
QR’: P = .086) prior to and with all three parameters following (QR: 
P = .016; QS: P = .022; QR’: P = .026) dobutamine challenge. Post hoc 
Tukey tests then demonstrated that prior to dobutamine adminis-
tration, QR durations were longer in aged Pgc-1β−/− than aged WT 
(P = .030), with indications of such differences in aged compared to 
young Pgc-1β−/− mice (P = .059). QS intervals were longer in aged 
Pgc-1β−/− than either young Pgc-1β−/− (P = .040) or aged WT mice 
(P = .024). Following dobutamine administration, QR durations were 
longer in aged Pgc-1β−/− than either aged WT (P = .035) or young 
Pgc-1β−/− (P = .030). QS durations were longer in aged Pgc-1β−/− than 
either young Pgc-1β−/− (P = .035) or aged WT mice (P = .026). QR’ 
durations were longer in aged Pgc-1β−/− mice than either aged WT 
(P = .039) or young Pgc-1β−/− mice (P = .017).
2.5 | Pgc-1β−/− hearts show shortened ventricular 
recovery times after adrenergic challenge
Age and genotype exerted contrasting effects on ventricular recovery 
times. Genotype affected all three measures of such recovery (RTc, 
R’Tc and STc durations; P = .0098, P = .0014 and P = .0029, respec-
tively) (Table 4). In contrast, age did not significantly affect any of 
these recovery parameters, nor were there any interactive effects of 
age and genotype. Post hoc testing showed that (for all parameters) 
the difference lay in findings obtained post- dobutamine challenge; 
there were no differences due to age, genotype or their interaction 
prior to dobutamine administration. Following dobutamine admin-
istration all three parameters showed a marked effect of genotype 
(P = .015, P = .021 and P = .0067 respectively) but no other effects. 
Post hoc Tukey tests showed that Pgc-1β−/− showed significantly 
shorter RTc, R’Tc and STc intervals than WT mice (P = .0053, P = .018 
and P = .0080 respectively). Thus, all three recovery parameters were 
highly concordant confirming that the Pgc-1β ablation significantly 
shortened ventricular recovery parameters (Table 5).
2.6 | Emergence of a short- QT phenotype in  
Pgc-1β−/− animals
The QTc interval has traditionally been used as a marker for repolarisa-
tion abnormalities in that the electrocardiographic phenotype is usu-
ally caused by a defect in ventricular recovery. However, it is more 
accurate to describe the QTc interval as a parameter that describes the 
combined durations of both activation and recovery i.e. the duration of 
ventricular excitation. The onset of ventricular activation is represented 
by the Q wave deflection; the C wave trough was taken to represent 
the end of ventricular recovery and hence used for calculation of the 
QT interval in the present study (Figure 1). Genotype, but neither age 
TABLE  2 Electrocardiographic features related to sino- atrial, atrio- ventricular and atrial conduction
WT Pgc-1β−/−
Young Aged Young Aged
(A) Heart rate response
Mean heart rate prior to dobutamine challenge 
(Hz)
6.29 ± 0.15 7.08 ± 0.16 6.32 ± 0.38 6.81 ± 0.59
Mean heart rate following dobutamine challenge 
(Hz)
9.10 ± 0.19 9.12 ± 0.15 8.33 ± 0.40 8.25 ± 0.39
Peak heart rate following dobutamine challenge 
(Hz)
9.32 ± 0.21 9.66 ± 0.32 8.51 ± 0.40 8.41 ± 0.39
(B) Atrial conduction
P- wave duration prior to dobutamine challenge 
(ms)
26.08 ± 0.50 25.57 ± 1.06 26.06 ± 0.47 27.64 ± 0.67
P- wave duration following dobutamine challenge 
(ms)
25.43 ± 0.58 26.08 ± 0.79 26.21 ± 0.48 26.90 ± 0.86
(C) AV conduction
Mean PR interval prior to dobutamine challenge 
(ms)
54.20 ± 2.57 63.26 ± 4.89 56.35 ± 5.56 66.62 ± 4.25
Mean PR interval following dobutamine challenge 
(ms)
52.53 ± 2.22 53.61 ± 2.76 58.38 ± 5.41 76.95 ± 9.54
Hearts showing decreased PR interval following 
dobutamine challenge
5 of 5 6 of 6 5 of 9 1 of 6
Hearts showing increased PR interval following 
dobutamine challenge
0 of 5 0 of 6 4 of 9 5 of 6
Electrocardiographic features gave (A) heart rates responses in studies of young WT (n = 5), aged WT (n = 8), young Pgc-1β−/− (n = 9) and aged Pgc-1β−/− 
mice (n = 6), in which two of the aged WT showed AV dissociation within the ECG analysis window. Studies of atrial (B) and AV (C) conduction were 
therefore based on young WT (n = 5), aged WT (n = 6), young Pgc-1β−/− (n = 9) and aged Pgc-1β−/− mice (n = 6) respectively.
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(P = .083) nor interactions between age and genotype (P = .075), sig-
nificantly affected QTc interval (P = .0071) (Table 6). ANOVA indicated 
no differences between groups at baseline. Following dobutamine 
challenge, genotype (P = .032), but not age affected QTc interval. Post 
hoc Tukey HSD tests revealed that, following dobutamine administra-
tion, young Pgc-1β−/− had shorter QTc intervals than both young WT 
(P = .026) and aged WT mice (P = .041). There was also a trend to-
wards young Pgc-1β−/− mice having shorter QTc intervals than aged 
Pgc-1β−/− mice (P = .094). Thus, Pgc-1β−/− mice had shorter QTc inter-
vals than their WT counterparts with most of the effect arising from 
shortening of the QTc intervals in young Pgc-1β
−/− mice.
3  | DISCUSSION
The ECG yields much prescient and strategic clinical electrophysiologi-
cal information as a primary investigational tool. Its recent experimental 
application had demonstrated valuable insights into electrophysiologi-
cal abnormalities in murine hearts modelling clinical arrhythmic condi-
tions. Cellular energetic dysfunction following metabolic disturbances 
is increasingly recognised as important factor in the aetiology of such 
atrial and ventricular arrhythmias. Destabilisation of inner mitochondrial 
membrane potentials results in approximately 10- fold increases in re-
active oxygen species production,25 in turn affecting maximum Na+25 
and K+ current,26 sarcolemmal KATP channel function, Na
+ and L- type 
Ca2+ channel inactivation kinetics and late Na+ current. They also affect 
ryanodine receptor function alterations in which affect surface mem-
brane excitability and intracellular Ca2+ homeostasis.27-29 Mitochondria 
are also the main cardiomyocyte ATP source and ATP/ADP depletion 
increases sarcolemmal ATP- sensitive K+ channel (sarcKATP) open prob-
abilities affecting action potential duration (APD), effective refractory 
period (ERP) and heterogenous current sinks potentially causing current- 
load mismatch.30 These cellular mechanisms could in turn potentially 
give rise to potentially pro- arrhythmic effects on cell- cell coupling,31 AP 
conduction25 and AP repolarisation.26 There may also be an appearance 
of alternans and Ca2+ mediated triggering phenomena.27 The Pgc-1β 
genetic modification has thus been associated with altered ion chan-
nel function and ventricular arrhythmias in Langendorff- perfused heart 
preparations.15
ECG alterations accompanying the associated mitochondrial dys-
function were therefore investigated in intact anaesthetised Pgc-1β−/− 
mice lacking the transcriptional coactivator Pgc-1β. The present study 
therefore yielded electrophysiological features associated with Pgc-1β 
ablation in the in vivo system with intact autonomic innervation and 
normal cardiac mechanical function, building upon earlier reports from 
the cellular studies15 and ex vivo hearts.14 The pharmacological ma-
noeuvres involving dobutamine challenge in the latter studies would 
largely involve β1- adrenergic receptor activity, whereas the present in 
vivo studies could potentially further involve β2- adrenergic receptor 
mediated extracardiac changes which in the clinical setting are also 
known to influence arrhythmic risk.
The present experiments characterised the intervals separating 
specific ECG waveform components more closely than did previous 
studies. Quantitative statistical analysis of these steady state param-
eters then employed two way factorial MANOVA testing for interact-
ing and non- interacting effects of age and genotype before and after 
dobutamine challenge. The presence of significant differences then 
prompted further, two way factorial ANOVA to ascertain whether 
the difference occurred before or following dobutamine application. 
Finally, appropriate Tukey HSD tests assessed for particular differ-
ences between individual parameters. Peak heart rates following 
dobutamine challenge were analysed by themselves by a two way fac-
torial ANOVA followed by post hoc Tukey tests.
The ECG analysis demonstrated a range of age- dependent ab-
normalities associated with the Pgc-1β−/− genotype. The predomi-
nant ECG pattern in both young and aged, WT and Pgc-1β−/− mice 
was one of sinus rhythm. Any ischaemic ECG changes observed were 
associated with age but were not specific to Pgc-1β−/− or WT gen-
otypes, suggesting that there was no underlying difference in vas-
cular as opposed to primary cardiomyocyte function between the 
two groups. However, we demonstrated for the first time blunted 
chronotropic responses to dobutamine challenge in an intact Pgc-
1β−/− mammalian system despite heart rate variabilities suggesting 
unchanged autonomic backgrounds. Previous reports had demon-
strated compromised heart rate responses in ex vivo Langendorff- 
perfused Pgc-1β−/− hearts following dobutamine challenge.14 These 
results together suggest that the impaired heart rate response of 
Pgc-1β−/− hearts does not reflect generalised autonomic dysfunction 
but rather alterations in the intrinsic myocardial response to dobu-
tamine. Ageing did not affect this chronotropic response, implicating 
the mutation as opposed to background deterioration of maximal 
heart rate with age.
F IGURE  5 Mean heart rates in the 5 minute analysis window 
before and after dobutamine administration in young and aged WT 
and Pgc-1β−/− mice
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Aged mice, independent of genotype, also showed episodes of 
isorhythmic AV dissociation with dobutamine challenge. During these 
episodes regular ventricular responses were seen, with normal, nar-
row QRS complexes despite the absence of a fixed PR interval, even 
when P- wave complexes were buried within the ventricular signal. 
These findings suggest that the murine SAN is vulnerable to degen-
erative changes with age, with appearances of supraventricular, most 
likely junctional, pacemaker foci intermittently dictating the ventricu-
lar rate. Pgc-1β−/− ablation also appeared to cause a more generalised 
defect also affecting the AVN. A significant proportion of Pgc-1β−/−, 
particularly aged, mutants, demonstrated an abnormal negatively 
dromotropic response to dobutamine challenge, suggesting pro-
gressive deterioration in AVN function in Pgc-1β−/− hearts with age. 
Furthermore, mice showing this abnormal AVN function showed more 
pronounced blunting in their chronotropic response to dobutamine, 
relating an AVN dysfunction to the chronotropic deficit observed here.
Pathological bradycardic rhythms secondary to cardiac conduction 
system disease are known to occur with ageing, often necessitating 
permanent pacemaker implantation. Progressive fibrotic change is a 
recognised feature of cardiac ageing in both animal32,33 and human 
studies.34 Fibrotic change could directly disrupt gap junction function, 
increasing tissue resistance,35 or increase fibroblast- cardiomyocyte 
coupling, increasing effective membrane capacitance.36 More re-
cent studies indeed implicate abnormal gap junction function in both 
SAN and AVN disease.37,38 Interestingly, oxidative stress, associated 
with mitochondrial impairment increases transforming growth factor 
(TGF)- β activity,39 in turn implicated in such age- related myocardial 
fibrosis.40 Conversely augmented mitochondrial anti- oxidant capacity 
protects against features of cardiac ageing including fibrotic change.41 
Mitochondrial dysfunction could also impair gap junction function 
through elevating intracellular [Ca2+] or altering connexin phosphor-
ylation through oxidative stress.42 Finally, the range of ionic currents 
including RyR2 channel function43 involved in SAN and AVN activity, 
are potentially modifiable by mitochondrial dysfunction. Isolated car-
diomyocytes from Pgc-1β−/− hearts have previously been reported to 
display altered diastolic Ca2+ transients in keeping with abnormal RyR2 
function.15
ECG deflections related to ventricular activation and recovery 
confirmed previous reports that murine ECGs lack well- defined ST 
segments.17,44 The murine ECG shows a R’ wave deflection, immedi-
ately following the S wave not seen in the human ECG. This is fol-
lowed by a further but variably reported deflection which has not been 
F IGURE  6  (A, B) Poincare plots pre- (A) and post- dobutamine (B) in young (a,b) and aged (c,d), WT (a,c) and Pgc- 1β-/- hearts (b,d) and (C, D) 
the standard deviations (SDs) of their ΔRR intervals before (C) and following dobutamine challenge (D)
135
145
155
165
175
135 145 155 165 175
RRn (ms)
R
R
n+
1
(m
s)
a
150
160
170
180
190
150 160 170 180 190
RRn (ms)
R
R
n+
1
(m
s )
b
135
145
155
165
175
135 145 155 165 175
RRn (ms)
R
R
n+
1
(m
s)
c
170
180
190
200
210
170 180 190 200 210
RRn ms
R
R
n+
1
m
s
d
90
100
110
120
130
90 100 110 120 130
RRn (ms)
R
R
n+
1
(m
s)
a
120
130
140
150
160
120 130 140 150 160
RRn (ms)
R
R
n+
1
(m
s)
b
90
100
110
120
130
90 100 110 120 130
RRn (ms)
R
R
n+
1
(m
s)
c
120
130
140
150
160
120 130 140 150 160
RRn ms
R
R
n+
1
m
s
d
(A) (B)
0
2
4
6
8
10
12
Yo
un
g W
T
Ag
ed
 W
T
Ag
ed
 P
gc
−1
ß
−/−
0
1
2
3
Yo
un
g W
T
Yo
un
g 
Pg
c−
1ß
−/−
Ag
ed
 W
T
Ag
ed
 Pg
c−
1ß
−/−
Yo
un
g 
Pg
c−
1ß
−/−
SD
 o
f Δ
R
R
(C) (D)
SD
 o
f Δ
R
R
182  |     AHMAD et Al.
systematically identified or formally correlated with particular action 
potential components. This variability may be attributed to the greater 
rostro- caudal anatomical alignment of the mouse heart in the thoracic 
cavity and variations in limb positioning during experimental recording 
between reports, with consequent variations in the effective position-
ing of the centre of the Einthoven triangle relative to the heart. Thus, 
although we also identified C waves, small changes in lead positioning 
could lead to its apparent disappearance in one or both ECG leads. 
This may account for the controversy concerning its inconsistent 
appearance.17
The onset of ventricular recovery in the murine ECG has been 
considered to occur from time points ranging from the S wave nadir 
to the R’ peak. A number of authors have suggested that the late 
component of the R’ wave or the R’ wave in totality is in fact part 
of ventricular repolarisation.16,18,44 Others suggested that inclusion 
of the R’ wave may lead to systematic overestimation of ventricular 
activation, whilst its exclusion in genetically modified mouse mod-
els, such as that of the Brugada syndrome, which displays slowed 
conduction, may lead to underestimation of ventricular activation 
times.18
We accordingly explored a set of related recovery parameters 
that utilised both the S wave nadir and peak of the R’ wave as cut- 
off separating ventricular activation and recovery phases. Each pa-
rameter is likely to capture activation and recovery in different areas 
of myocardium, reflecting the non- simultaneous nature of electrical 
activity in the myocardium. This increased the robustness of our anal-
ysis and permitted us to assess the possibility of early repolarisation in 
our genetic model. The statistical analysis of the different parameters 
of recovery and activation were highly concordant. Pgc-1β−/− hearts 
showed a prolongation of all such measures of ventricular activation 
with age whether before or following adrenergic stress, in an absence 
of independent effects of age or genotype. These findings parallel the 
reduced conduction velocities reported in other arrhythmic genetic 
models. These had accompanied either fibrotic change or reduced 
Na+ currents resulting from Nav1.5 deficiency in Scn5a+/−32,33,45 and 
Scn5a+/ΔKPQ,21 or secondary to Ca2+ handling abnormalities in RyR2-
P2328S hearts.44,46,47 These findings are also compatible with reports 
that mitochondrial abnormalities could alter IK and therefore result in 
current- load mismatch.6,30
Pgc-1β−/− hearts also showed shorter recovery parameters than 
WT after dobutamine administration, without effects of age whether 
acting independently or interacting with genotype. Such shortened 
repolarisation intervals have also been implicated in arrhythmic risk. 
Human short QT syndrome is diagnosed using the J point to T peak 
interval that may represent the interval between the end of the ven-
tricular complex to the peak of the repolarisation wave.48 Short QT 
syndrome has been traced to HERG and other K+ channel mutations 
and more recently, Ca2+ channel function.49 The present findings are 
thus consistent with reported alterations in K+ conductance properties 
in the Pgc-1β−/− system that would also modify current- load match-
ing.15 These changes appeared to result in shortened QTc intervals for 
mutant mice with adrenergic stress. Although the mechanisms under-
lying these changes remain unclear, increased expression of Kcna5 was 
reported in the latter study and may contribute to the increased K+ 
conductance observed. Additionally, the opening and K+ conductance 
of the sarcKATP is linked to rising cellular ADP levels, therefore cor-
relating its activity to cellular metabolic status. Its activity is known to 
reduce the action potential duration and is thought to contribute to 
increased arrhythmic risk.50 Oxidative stress is also known to enhance 
sarcKATP activity; however the cellular mechanism are yet to be estab-
lished but may occur through depletion of cellular ATP. Nevertheless, 
the effects of ROS upon sarcKATP activity could be attenuated through 
inhibition of protein kinase C, protein kinase G and calcium- calmodulin 
kinase II but not protein kinase A, providing some insights into the 
pathways involved.51
Finally, these findings prompted us to measure QTc intervals re-
flecting the total activation times of the ventricular myocardium. Pgc-
1β−/− mice showed shorter QTc intervals than their WT counterparts. 
Most of this effect seemed to arise in the young mutant mice, though 
this was not significant. This is in contrast to the shortened repolarisa-
tion parameters in both young and aged Pgc-1β−/−. This likely reflects 
the additional, prolonged, depolarisation parameters in aged Pgc-1β−/− 
mice, offsetting to some degree the shortening in the repolarisation 
parameters.
In summary, ECG analysis demonstrates a range of electrocar-
diographic abnormalities associated with the Pgc-1β−/− genotype 
and those features particularly vulnerable to advanced age. Thus, 
F IGURE  7 PR intervals reflecting paradoxical AV dysfunction 
before and following dobutamine challenge in (A) young WT and (B) 
aged Pgc-1β−/− mouse
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Pgc-1β−/− mice show reduced sino- atrial responses to dobutamine, 
paradoxical atrioventricular nodal function increasing in prevalence 
with age, slowed ventricular activation with ageing and shortened re-
covery parameters after dobutamine challenge.
4  | METHODS
4.1 | Animals
This research has been regulated under the Animals (Scientific 
Procedures) Act 1986 Amendment Regulations 2012 following ethi-
cal review by the University of Cambridge Animal Welfare and Ethical 
Review Body (AWERB). The experiments also conformed to the Guide 
for the Care and Use of Laboratory Animals, US National Institutes 
of Health (NIH Publication No. 85- 23, revised 1996). Mice from a 
consistent C57/B6 background to avoid possible strain- related con-
founds, were housed in an animal facility at 21°C with 12- hour light/
dark cycles. Animals were fed sterile chow (RM3 Maintenance Diet, 
SDS, Witham, Essex, UK) and had free access to water. Wild Type 
C57/B6 and Pgc-1β−/− adult mice were bred for the experimental pro-
tocols. Mice were divided into four groups: groups 1 and 2 consisted 
of mice aged between 12 and 16 weeks, and consisted respectively of 
littermate WT controls (n = 5) and Pgc-1β−/− mice (n = 9). Group 3 was 
composed of aged (greater than 52 weeks) littermate WT controls 
(n = 8). Group 4 consisted of Pgc-1β−/− mice of age similarly greater 
than 52 weeks (n = 6). These timings parallel those used in previous 
studies in transgenic Scn5a+/− mice which reported increased fibrotic 
and electrophysiological alterations at ages above 12 months.45 The 
TABLE  4 Electrocardiographic recovery intervals
WT Pgc-1β−/−
Young Aged Young Aged
RTc duration before dobutamine challenge 
(ms)
29.00 ± 0.54 30.60 ± 0.87 28.51 ± 1.05 28.89 ± 0.87
RTc duration following dobutamine 
challenge (ms)
33.43 ± 0.77 33.75 ± 0.44 31.41 ± 0.86 31.79 ± 0.41
R’Tc duration before dobutamine challenge 
(ms)
23.15 ± 0.45 23.64 ± 0.71 22.55 ± 0.91 22.55 ± 0.56
R’Tc duration following dobutamine 
challenge (ms)
25.97 ± 0.43 25.88 ± 0.55 24.16 ± 0.66 24.40 ± 0.29
STc duration before dobutamine challenge 
(ms)
26.35 ± 0.38 27.65 ± 0.77 25.79 ± 0.92 26.06 ± 0.55
STc duration following dobutamine challenge 
(ms)
30.13 ± 0.68 30.31 ± 0.50 28.00 ± 0.71 28.40 ± 0.30
Electrocardiographic measurements made in RTc, R’Tc and STc durations before and following dobutamine challenge in young WT (n = 5), aged WT (n = 8), 
young Pgc-1β−/− (n = 9) and aged Pgc-1β−/− (n = 6) mice. One young and one aged Pgc-1β−/− mouse were excluded as these showed paradoxical dromotropic 
effects that lead to prolonged PR intervals and P waves that interfered with determinations of the end of the C wave to give the following n values: young 
WT (n = 5), aged WT (n = 8), young Pgc-1β−/− (n = 8) and aged Pgc-1β−/− (n = 5).
TABLE  3 Electrocardiographic activation intervals
WT Pgc-1β−/−
Young Aged Young Aged
QR duration before dobutamine challenge 
(ms)
6.85 ± 0.67 5.89 ± 0.63 6.20 ± 0.48 8.35 ± 0.52
QR duration following dobutamine 
challenge (ms)
7.14 ± 0.75 6.12 ± 0.60 6.12 ± 0.48 8.56 ± 0.56
QS duration before dobutamine challenge 
(ms)
10.19 ± 0.47 9.43 ± 0.45 9.67 ± 0.45 11.78 ± 0.7
QS duration following dobutamine challenge 
(ms)
10.60 ± 0.62 9.76 ± 0.40 9.91 ± 0.43 12.07 ± 0.77
QR’ duration before dobutamine challenge 
(ms)
14.24 ± 0.60 14.22 ± 0.40 13.82 ± 0.34 16.20 ± 0.92
QR’ duration following dobutamine 
challenge (ms)
14.95 ± 0.41 14.39 ± 0.55 14.15 ± 0.38 16.72 ± 0.89
Electrocardiographic measurements made in QR, QS and QR’ durations before and following dobutamine challenge in young WT (n = 5), aged WT (n = 8), 
young Pgc-1β−/− (n = 9) and aged Pgc-1β−/− mice (n = 6).
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latter two groups used here accordingly consisted of animals above 
this age to investigate the effects of age on electrocardiographic pa-
rameters in these mice.
4.2 | Electrocardiography
Mice were anaesthetised with tribromoethanol (avertin: 2,2,2 tri-
methylethanol, Sigma Aldrich, Poole, UK) administered into the in-
traperitoneal space with a 27G hypodermic needle. They were then 
weighed, placed supine on a warmed (37°C) platform, and their limbs 
secured with adhesive tape to minimise movement artefact and en-
able correct lead positioning. Three 2- millimetre diameter electrodes 
(MLA1204; ADInstruments, Colorado Springs, CO, USA) placed in the 
right forelimb, left forelimb and left hindlimb respectively enabled 
lead I and lead II ECG recordings. The electrodes were connected to a 
4- channel NL844 pre- amplifier whose outputs were then led through 
4- channel NL820 isolator and NL135 low- pass filter units (set at a 
1.0- kHz cut- off and with a 50- Hz notch) within a NL900D chassis 
and power supply (Neurolog- Digitimer, Hertfordshire, UK). To reduce 
electrical noise, all recordings were carried out within a grounded 
Faraday cage. Signals were sampled at 5 kHz and analogue- to- digital 
conversion employed a CED 1401c interface (Cambridge Electronic 
Design, Cambridge, UK). This then conveyed the signal to a com-
puter for display and recording using Spike II software (Cambridge 
Electronic Design).
ECG recordings commenced immediately following electrode at-
tachment in anaesthetised animals. These were continued for 5 min-
utes to permit preparations to reach a steady state, and for a further 
5 minutes to obtain traces for quantitative analysis. Dobutamine hy-
drochloride (3 mg/kg; Sigma Aldrich) was then administered into the 
intraperitoneal space. ECG recording was then continued until a new 
steady state was reached. A further 5 minute recording period pro-
vided traces for quantitative ECG analysis following pharmacological 
challenge.
4.3 | Digital signal processing
All analysis employed custom- written software in the open- source R 
programming language. Data was imported into the R program. An 
infinite impulse response (IIR) high pass Butterworth filter of order 
2 was designed and the signal passed through to eliminate baseline 
drift. The signal was filtered in both forward and reverse directions 
to negate effects of any phase shift. A low- pass Savitzky- Golay algo-
rithm was then applied. R peak fiducial points were identified with a 
peak- finding algorithm used to detect QRS complexes. An iterative 
process determined the signal envelope and an adaptive threshold 
was used to identify time points in the signal that were greater than 
threshold in the continuous ECG signal. QRS complex timing positions 
were determined; peaks on a more substantive upward or downward 
trend were disregarded in favour of the peak with the larger absolute 
value. If multiple peaks were detected within 2 milliseconds the peaks 
were analysed again and the larger maximum value taken as the cor-
rect peak, and the smaller peak discarded. In addition, all detections 
TABLE  5 Electrocardiographic recovery intervals: WT and 
Pgc1β−/− compared
WT Pgc-1β−/−
RTc duration before dobutamine 
challenge (ms)
29.99 ± 0.60 28.65 ± 0.70
RTc duration following 
dobutamine challenge (ms)
33.63 ± 0.38 31.53 ± 0.57
R’Tc duration before dobu-
tamine challenge (ms)
23.45 ± 0.46 22.55 ± 0.58
R’Tc duration following 
dobutamine challenge (ms)
25.91 ± 0.37 24.24 ± 0.44
STc duration before dobutamine 
challenge (ms)
27.15 ± 0.51 25.89 ± 0.59
STc duration following 
dobutamine challenge (ms)
30.24 ± 0.39 28.13 ± 0.48
Electrocardiographic measurements made in RTc, R’Tc and STc durations 
before and following dobutamine challenge in young WT (n = 5), aged WT 
(n = 8), young Pgc-1β−/− (n = 9) and aged Pgc-1β−/− mouse (n = 6). One 
young and one aged Pgc-1β−/− mouse were excluded as these showed 
paradoxical dromotropic effects that led to prolonged PR intervals and P 
waves that interfered with determinations of the end of the C wave to give 
the following n values: young WT (n = 5), aged WT (n = 8), young Pgc-1β−/− 
(n = 8) and aged Pgc-1β−/− (n = 5). This gave total n values of WT and Pgc-
1β−/− of 13 in both cases.
WT Pgc-1β−/−
Young Aged Young Aged
Mean QTc before 
dobutamine 
challenge (ms)
34.43 ± 0.20 35.60 ± 0.79 33.37 ± 1.12 35.78 ± 1.18
Mean QTc following 
dobutamine 
challenge (ms)
40.23 ± 0.45 39.64 ± 0.52 37.01 ± 0.87 39.77 ± 0.81
Electrocardiographic measurements made in QTc durations before and following dobutamine challenge 
in young WT (n = 5), aged WT (n = 8), young Pgc-1β−/− (n = 9) and aged Pgc-1β−/− (n = 6) mice. One 
young and one aged Pgc-1β−/− mouse were excluded as these showed paradoxical dromotropic effects 
that led to prolonged PR intervals and P waves that interfered with determinations of the end of the C 
wave to give the following n values: young WT (n = 5), aged WT (n = 8), young Pgc-1β−/− (n = 8) and 
aged Pgc-1β−/− (n = 5). This gave total n values of WT and Pgc-1β−/− of 13 in both cases.
TABLE  6 Mean electrocardiographic 
QTc durations
     |  185AHMAD et Al.
were visually verified. P- waves were analysed independently of QRS 
complexes by deleting the QRS complexes and subsequent isolation 
of the P- wave parameters. This analysis thus made no assumption of 
QRS complexes being preceded by P- waves. Analysis was performed 
on 300 second periods of ECG data immediately prior to and follow-
ing administration of dobutamine hydrochloride. The effect of dobu-
tamine was judged from observed ECG parameter changes. Figure 1 
depicts a typical murine ECG recording with parameters calculated 
based upon this archetypal signal. Intervals were corrected using the 
formula previously described.52
4.4 | Statistical analysis
Statistical analysis used the R programming language. Data sets 
were first tested for normality with the Shapiro- Wilk test before 
statistical analysis using two way factorial multivariate analysis of 
variance, i.e. MANOVA with Pillai trace. The data sets analysed were 
the steady state heart rates, P- wave durations, PR intervals, activa-
tion parameters of QR, QS and QR’ durations, recovery parameters 
of RTc, R’Tc and STc durations, as well as the QTc interval. Each of 
these were measured from ECG records of young and aged, WT and 
Pgc-1β−/− mice respectively, both before and following dobutamine 
challenge. The initial MANOVA tests examined each parameter for 
significant effects of age, genotype or interactive effects of age and 
genotype either prior to or following dobutamine challenge. Where 
MANOVA testing indicated existence of significant differences prior 
to dobutamine administration, further ANOVA analyses were con-
ducted on pre- drug parameters testing for effects of genotype, age 
or interacting effects of the two. The presence of significant effects 
then prompted pairwise Tukey honest significant difference test-
ing of differences between pairs of individual parameters. Similarly, 
where significant differences were indicated post- dobutamine, a 
similar procedure of significance testing was performed examin-
ing for significant effects post drug challenge. Peak heart rates that 
were obtained following dobutamine challenge, were analysed by a 
two way factorial ANOVA: there was no meaningful peak heart rate 
pre- dobutamine. These were then also followed by post hoc Tukey 
tests for differences between individual parameters if prompted by 
the significance levels.
A P < .05 following Bonferroni correction where appropriate was 
considered to indicate a significant difference. Murine ECGs which 
demonstrated P- wave dissociation in the analysis period were dis-
carded for P- wave dependent parameter analysis. All diagrams were 
produced with the R- grammar of graphics package.
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